Hikma Intl Pharms Drug Patent Portfolio
Hikma Intl Pharms owns 1 orange book drug protected by 5 US patents Given below is the list of Hikma Intl Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8927607 | Methods of colchicine administration | 22 Aug, 2033 | Active |
| US9399036 | Methods of colchicine administration | 22 Aug, 2033 | Active |
| US9555029 | Methods of colchicine administration | 22 Aug, 2033 | Active |
| US9675613 | Methods of colchicine administration | 22 Aug, 2033 | Active |
| US9789108 | Methods of colchicine administration | 22 Aug, 2033 | Active |
Latest Legal Activities on Hikma Intl Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Hikma Intl Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Jan, 2024 | US9399036 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Apr, 2021 | US9789108 |
|
Correspondence Address Change
Critical
| 06 Nov, 2020 | US9675613 (Litigated) |
|
Correspondence Address Change
Critical
| 06 Nov, 2020 | US9399036 |
|
Correspondence Address Change
Critical
| 06 Nov, 2020 | US9789108 |
|
Correspondence Address Change
Critical
| 06 Nov, 2020 | US9555029 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Aug, 2020 | US9675613 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 02 Jul, 2020 | US9555029 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2019 | US9399036 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 17 Oct, 2017 | US9789108 |
|
Recordation of Patent Grant Mailed
Critical
| 17 Oct, 2017 | US9789108 |
|
Email Notification
Critical
| 28 Sep, 2017 | US9789108 |
|
Issue Notification Mailed
Critical
| 27 Sep, 2017 | US9789108 |
| Dispatch to FDC | 13 Sep, 2017 | US9789108 |
|
Application Is Considered Ready for Issue
Critical
| 12 Sep, 2017 | US9789108 |
Hikma Intl Pharms's Family Patents
Recently granted tentative Approvals to Hikma Intl Pharms
These tentative approvals reflect continued regulatory progress across both innovative and generic submissions related to Hikma Intl Pharms's portfolio.
Generic tentative approvals
| Drug Name | Active Ingredient | Submission Type | Submission Category | Submission Date |
|---|---|---|---|---|
| Sugammadex | Sugammadex |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 27 Jun, 2025 |
| Levofloxacin | Levofloxacin |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 31 Jan, 2011 |
| Rosiglitazone Maleate | Rosiglitazone Maleate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | (Not Available) | 08 Dec, 2009 |
Explore deeper patents analysis
Hikma Intl Pharms Drug List
Given below is the complete list of Hikma Intl Pharms's drugs and the patents protecting them.
1. Mitigare
Mitigare is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8927607 | Methods of colchicine administration |
22 Aug, 2033
(7 years from now)
| Active |
| US9399036 | Methods of colchicine administration |
22 Aug, 2033
(7 years from now)
| Active |
| US9555029 | Methods of colchicine administration |
22 Aug, 2033
(7 years from now)
| Active |
| US9675613 | Methods of colchicine administration |
22 Aug, 2033
(7 years from now)
| Active |
| US9789108 | Methods of colchicine administration |
22 Aug, 2033
(7 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Mitigare's drug page